Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, September 28, 2020
Samsung Biologics has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors.
read more
Samsung BioLogics and GI Innovation have signed a Contract Development Organization (CDO) contract for immunochemotherapy.
read more
Thursday, January 12, 2023
Samsung Biologics, a leading contract development and manufacturing organization (CDMO), was awarded the Sustainable Markets Initiative’s Terra Carta Seal.
read more
Wednesday, December 13, 2017
Samsung BioLogics has been licensed by the Europe’s EMA for the first monoclonal antibody Drug Substance at its second plant.
read more
Samsung Biologics announced that the company was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainability management.
read more
Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the FDA for its second plant.
read more
Samsung Biologics signed an agreement with the Incheon Free Economic Zone (IFEZ) on July 18th to build out its second Bio Campus.
read more
Samsung BioLogics announced on October 1st, 2018 that its Plant 3 has become cGMP ready and started production (OOF, out of freezing) after its successful validation.
read more
Samsung Biologics has successfully renewed its ISO 27001 certification (Information Security Management System) and obtained ISO 27017 certification (Information Security in cloud services) and ISO 37001 certification (Anti-bribery management systems...
read more
Wednesday, December 30, 2020
Samsung Biologics announced John Rim as its President and CEO.
read more
Samsung Biologics has announced an all-cash public tender offer to acquire PolyPeptide Group AG, valuing the peptide-focused contract development and manufacturing organization at approximately CHF 1.46 billion.
read more
Tuesday, September 01, 2026
Samsung Biologics has published the formal prospectus for its planned acquisition of PolyPeptide Group AG, offering about $55.70 in cash per share in a transaction that values the Swiss peptide manufacturer’s equity at approximately $1.83 billion.
read more
Samsung Biologics, a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL™ and DEVELOPICK™ – at this year's BioProcess International Conference and ...
read more
Samsung Biologics, a contract development and manufacturing organization (CMDO), celebrated the one-year mark of Live Virtual Tour (LVT), a platform to provide remote site inspections for clients and regulatory agencies. The tool was developed and ...
read more
Samsung BioLogics has successfully performed N-1 (3,000L) perfusion with Alternating Tangential Flow device to supply the 15,000L commercial production process in the Plant 3 facility at its manufacturing site in Songdo, S. Korea.
read more